AC Immune Announces Interim 12-Month Data From Its Phase 1b/2 ABATE Trial Of ACI-24 In Prodromal Alzheimer’s Disease; ACI-24 Generally Safe And Well Tolerated in First Three Cohorts

Loading news article.

AC Immune Announces Interim 12-Month Data From Its Phase 1b/2 ABATE Trial Of ACI-24 In Prodromal Alzheimer’s Disease; ACI-24 Generally Safe And Well Tolerated in First Three Cohorts | WAPE

AC Immune Announces Interim 12-Month Data From Its Phase 1b/2 ABATE Trial Of ACI-24 In Prodromal Alzheimer’s Disease; ACI-24 Generally Safe And Well Tolerated in First Three Cohorts

Article summary

Related companies

Comments —